Open AccessSevere Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial*
Author(s) -
Elliott BennettGuerrero,
Jamie Romeiser,
Lillian R. Talbot,
Tahmeena Ahmed,
Linda Mamone,
Sunitha M. Singh,
Janet Hearing,
Huda Salman,
Dishaw D Holiprosad,
Alex T. Freedenberg,
Jason A. Carter,
Nicholas Browne,
Megan E. Cosgrove,
Margaret Shevik,
Laura M Generale,
Margaret A Andrew,
Sharon Nachman,
Bettina C. Fries
Publication year - 2021
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000005066
Subject(s) - medicine , interquartile range , randomized controlled trial , clinical endpoint , coronavirus , randomization , gastroenterology , disease , covid-19 , infectious disease (medical specialty)
Four peer-reviewed publications have reported results from randomized controlled trials of convalescent plasma for coronavirus disease 2019 infection; none were conducted in the United States nor used standard plasma as a comparator. To determine if administration of convalescent plasma to patients with coronavirus disease 2019 increases antibodies to severe acute respiratory syndrome coronavirus 2 and improves outcome.